{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Herbal formulation", "Hereditary ataxia", "Medicinal mushroom", "Medicinal plant", "Natural remedy"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33509239", "DateRevised": {"Year": "2021", "Month": "01", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "01", "Day": "28"}], "Language": ["eng"], "ELocationID": ["15", "10.1186/s13020-020-00414-x"], "Journal": {"ISSN": "1749-8546", "JournalIssue": {"Volume": "16", "Issue": "1", "PubDate": {"Year": "2021", "Month": "Jan", "Day": "28"}}, "Title": "Chinese medicine", "ISOAbbreviation": "Chin Med"}, "ArticleTitle": "Therapeutic roles of natural remedies in combating hereditary ataxia: A systematic review.", "Pagination": {"StartPage": "15", "MedlinePgn": "15"}, "Abstract": {"AbstractText": ["Hereditary ataxia (HA) represents a group of genetically heterogeneous neurodegenerative diseases caused by dysfunction of the cerebellum or disruption of the connection between the cerebellum and other areas of the central nervous system. Phenotypic manifestation of HA includes unsteadiness of stance and gait, dysarthria, nystagmus, dysmetria and complaints of clumsiness. There are no specific treatments for HA. Management strategies provide supportive treatment to reduce symptoms.", "This systematic review aimed to identify, evaluate and summarise the published literature on the therapeutic roles of natural remedies in the treatment of HA to provide evidence for clinical practice.", "A systematic literature search was conducted using the Preferred Reporting Items for Systematic Reviews\u00a0and Meta-Analyses (PRISMA). Web of Science, PubMed and Science Direct Scopus were thoroughly searched for relevant published articles from June 2007 to July 2020.", "Ten pre-clinical and two clinical studies were eligible for inclusion in this systematic review. We identified the therapeutic roles of medicinal plants Brassica napus, Gardenia jasminoides, Gastrodia elata, Ginkgo biloba, Glycyrrhiza inflata, Paeonia lactiflora, Pueraria lobata and Rehmannia glutinosa; herbal formulations Shaoyao Gancao Tang and Zhengan Xifeng Tang; and medicinal mushroom Hericium erinaceus in the treatment of HA. In this review, we evaluated the mode of actions contributing to their therapeutic effects, including activation of the ubiquitin-proteasome system, activation of antioxidant pathways, maintenance of intracellular calcium homeostasis and regulation of chaperones. We also briefly highlighted the integral cellular signalling pathways responsible for orchestrating the mode of actions.", "We reviewed the therapeutic roles of natural remedies in improving or halting the progression of HA, which warrant further study for applications into clinical practice."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anatomy, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia."}], "LastName": "Phang", "ForeName": "Michael Weng Lok", "Initials": "MWL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anatomy, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia."}], "LastName": "Lew", "ForeName": "Sze Yuen", "Initials": "SY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia."}], "LastName": "Chung", "ForeName": "Ivy", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Kuching, Sarawak, 94300, Malaysia."}], "LastName": "Lim", "ForeName": "William Kiong-Seng", "Initials": "WK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, China. drlimleewei@gmail.com."}], "LastName": "Lim", "ForeName": "Lee Wei", "Initials": "LW"}, {"Identifier": ["0000-0002-8292-4498"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anatomy, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia. wkahhui@um.edu.my."}], "LastName": "Wong", "ForeName": "Kah Hui", "Initials": "KH"}], "GrantList": [{"GrantID": "GPF003C-2019", "Agency": "Universiti Malaya", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Chin Med", "NlmUniqueID": "101265109", "ISSNLinking": "1749-8546"}, "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Akbar U, Ashizawa T. Ataxia. Neurol Clin. 2015;33(1):225\u2013248. doi: 10.1016/j.ncl.2014.09.004.", "ArticleIdList": ["10.1016/j.ncl.2014.09.004", "PMC4251489", "25432731"]}, {"Citation": "Albernaz PLM, Zuma e Maia FZ, Carmona S, Cal RVR, Zalazar G. The new neurotology: a comprehensive clinical guide. Cham: Springer; 2019. Ataxia; pp. 181\u201391."}, {"Citation": "Teive HAG, Ashizawa T. Primary and secondary ataxias. Curr Opin Neurol. 2015;28(4):413\u2013422. doi: 10.1097/WCO.0000000000000227.", "ArticleIdList": ["10.1097/WCO.0000000000000227", "PMC6516769", "26132530"]}, {"Citation": "Sarva H, Shanker VL. Treatment options in degenerative cerebellar ataxia: a systematic review. Mov Disord Clin Pract. 2014;1(4):291\u2013298. doi: 10.1002/mdc3.12057.", "ArticleIdList": ["10.1002/mdc3.12057", "PMC6183008", "30363941"]}, {"Citation": "Beaudin M, Matilla-Due\u00f1as A, Soong B-W, Pedroso JL, Barsottini OG, Mitoma H, Tsuji S, Schmahmann JD, Manto M, Rouleau GA, Klein C, Dupre N. The classification of autosomal recessive cerebellar ataxias: a consensus statement from the society for research on the cerebellum and ataxias task force. Cerebellum. 2019;18(6):1098\u20131125. doi: 10.1007/s12311-019-01052-2.", "ArticleIdList": ["10.1007/s12311-019-01052-2", "PMC6867988", "31267374"]}, {"Citation": "Buijsen RAM, Toonen LJA, Gardiner SL, van Roon-Mom WMC. Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias. Neurotherapeutics. 2019;16(2):263\u2013286. doi: 10.1007/s13311-018-00696-y.", "ArticleIdList": ["10.1007/s13311-018-00696-y", "PMC6554265", "30607747"]}, {"Citation": "Bird TD. Hereditary ataxia overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. GeneReviews\u00ae [Internet] Seattle: University of Washington; 2019.", "ArticleIdList": ["20301317"]}, {"Citation": "\u00d6z G, Iltis I, Hutter D, Thomas W, Bushara KO, Gomez CM. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. Cerebellum. 2011;10(2):208\u2013217. doi: 10.1007/s12311-010-0213-6.", "ArticleIdList": ["10.1007/s12311-010-0213-6", "PMC3089811", "20838948"]}, {"Citation": "Seidel K, Siswanto S, Brunt ERP, den Dunnen W, Korf H-W, R\u00fcb U. Brain pathology of spinocerebellar ataxias. Acta Neuropathol. 2012;124(1):1\u201321. doi: 10.1007/s00401-012-1000-x.", "ArticleIdList": ["10.1007/s00401-012-1000-x", "22684686"]}, {"Citation": "R\u00fcb U, Sch\u00f6ls L, Paulson H, Auburger G, Kermer P, Jen JC, Seidel K, Korf H-W, Deller T. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol. 2013;104:38\u201366. doi: 10.1016/j.pneurobio.2013.01.001.", "ArticleIdList": ["10.1016/j.pneurobio.2013.01.001", "23438480"]}, {"Citation": "Piccinin CC, D\u2019Abreu A. Neuroimaging in ataxias. In: Habas C, editor. The neuroimaging of brain diseases: structural and functional advances. Cham: Springer; 2018. pp. 215\u201332."}, {"Citation": "Meira AT, Arruda WO, Ono SE, de Carvalho Neto A, Raskin S, Camargo CHF, Teive HAG. Neuroradiological findings in the spinocerebellar ataxias. Tremor Other Hyperkinet Mov (N Y). 2019 doi: 10.7916/tohm.v0.682.", "ArticleIdList": ["10.7916/tohm.v0.682", "PMC6765228", "31632837"]}, {"Citation": "Vel\u00e1zquez-P\u00e9rez L, Rodr\u00edguez-Labrada R, Freund H-J, Auburger G. Spinocerebellar ataxia type 2. In: Gazulla J, editor. Spinocerebellar ataxia. Rijeka: InTech; 2012. pp. 77\u2013102."}, {"Citation": "Vel\u00e1zquez-P\u00e9rez LC, Rodr\u00edguez-Labrada R, Fernandez-Ruiz J. Spinocerebellar ataxia type 2: clinicogenetic aspects, mechanistic insights, and management approaches. Front Neurol. 2017;8:472. doi: 10.3389/fneur.2017.00472.", "ArticleIdList": ["10.3389/fneur.2017.00472", "PMC5601978", "28955296"]}, {"Citation": "Vale J, Bugalho P, Silveira I, Sequeiros J, Guimar\u00e3es J, Coutinho P. Autosomal dominant cerebellar ataxia: frequency analysis and clinical characterization of 45 families from Portugal. Eur J Neurol. 2010;17(1):124\u2013128. doi: 10.1111/j.1468-1331.2009.02757.x.", "ArticleIdList": ["10.1111/j.1468-1331.2009.02757.x", "19659750"]}, {"Citation": "de Assis AM, Saute JAM, Longoni A, Haas CB, Torrez VR, Brochier AW, Souza GN, Furtado GV, Gheno TC, Russo A, Monte TL, Castilhos RM, Schumacher-Schuh A, D\u2019 Avila R, Donis KC, de Mello Rieder CR, Souza DO, Camey S, Leotti VB, Jardim LB, Portela LV. Peripheral oxidative stress biomarkers in spinocerebellar ataxia type 3/Machado\u2013Joseph disease. Front Neurol. 2017;8:485.\u00a010.3389/fneur.2017.00485.", "ArticleIdList": ["PMC5611390", "28979235"]}, {"Citation": "Yang Z, Shi C, Zhou L, Li Y, Yang J, Liu Y, Mao C, Luo H, Xu G, Xu Y. Metabolic profiling reveals biochemical pathways and potential biomarkers of spinocerebellar ataxia 3. Front Mol Neurosci. 2019;12:159. doi: 10.3389/fnmol.2019.00159.", "ArticleIdList": ["10.3389/fnmol.2019.00159", "PMC6611058", "31316347"]}, {"Citation": "Adanyeguh IM, Henry P-G, Nguyen TM, Rinaldi D, Jauffret C, Valabregue R, Emir UE, Deelchand DK, Brice A, Eberly LE, \u00d6z G, Durr A, Mochel F. In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7. Mov Disord. 2015;30(5):662\u2013670. doi: 10.1002/mds.26181.", "ArticleIdList": ["10.1002/mds.26181", "PMC4397159", "25773989"]}, {"Citation": "Torres-Ramos Y, Montoya-Estrada A, Cisneros B, Tercero-P\u00e9rez K, Le\u00f3n-Reyes G, Leyva-Garc\u00eda N, Hern\u00e1ndez-Hern\u00e1ndez O, Maga\u00f1a JJ. Oxidative stress in spinocerebellar ataxia type 7 is associated with disease severity. Cerebellum. 2018;17(5):601\u2013609. doi: 10.1007/s12311-018-0947-0.", "ArticleIdList": ["10.1007/s12311-018-0947-0", "29876803"]}, {"Citation": "Brockmann K, Reimold M, Globas C, Hauser TK, Walter U, Machulla H-J, Rolfs A, Sch\u00f6ls L. PET and MRI reveal early evidence of neurodegeneration in spinocerebellar ataxia type 17. J Nucl Med. 2012;53(7):1074\u20131080. doi: 10.2967/jnumed.111.101543.", "ArticleIdList": ["10.2967/jnumed.111.101543", "22653791"]}, {"Citation": "Mundwiler A, Shakkottai VG. Autosomal-dominant cerebellar ataxias. Handb Clin Neurol. 2018;147:173\u2013185. doi: 10.1016/B978-0-444-63233-3.00012-9.", "ArticleIdList": ["10.1016/B978-0-444-63233-3.00012-9", "29325610"]}, {"Citation": "Jen JC, Graves TD, Hess EJ, Hanna MG, Griggs RC, Baloh RW. CINCH investigators. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain. 2007;130(10):2484\u20132493. doi: 10.1093/brain/awm126.", "ArticleIdList": ["10.1093/brain/awm126", "17575281"]}, {"Citation": "Choi K-D, Choi J-H. Episodic ataxias: clinical and genetic features. J Mov Disord. 2016;9(3):129\u2013135. doi: 10.14802/jmd.16028.", "ArticleIdList": ["10.14802/jmd.16028", "PMC5035943", "27667184"]}, {"Citation": "Hasan SM, D\u2019Adamo MC. Episodic ataxia type 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. GeneReviews\u00ae [Internet] Seattle: University of Washington; 2018.", "ArticleIdList": ["20301785"]}, {"Citation": "Mantuano E, Veneziano L, Spadaro M, Giunti P, Guida S, Leggio MG, Verriello L, Wood N, Jodice C, Frontali M. Clusters of non-truncating mutations of P/Q type Ca2+ channel subunit Cav2. 1 causing episodic ataxia 2. J Med Genet. 2004;41(6):e82. doi: 10.1136/jmg.2003.015396.", "ArticleIdList": ["10.1136/jmg.2003.015396", "PMC1735819", "15173248"]}, {"Citation": "Spacey S. Episodic ataxia type 2. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. GeneReviews\u00ae [Internet] Seattle: University of Washington; 2015."}, {"Citation": "Mascalchi M, Salvi F, Piacentini S, Bartolozzi C. Friedreich\u2019s ataxia: MR findings involving the cervical portion of the spinal cord. AJR Am J Roentgenol. 1994;163(1):187\u2013191. doi: 10.2214/ajr.163.1.8010211.", "ArticleIdList": ["10.2214/ajr.163.1.8010211", "8010211"]}, {"Citation": "Campuzano V, Montermini L, Molto MD, Pianese L, Coss\u00e9e M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Ca\u00f1izares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel J-L, Cocozza S, Koenig M, Pandolfo M. Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423\u20131427. doi: 10.1126/science.271.5254.1423.", "ArticleIdList": ["10.1126/science.271.5254.1423", "8596916"]}, {"Citation": "McKinnon PJ. ATM and the molecular pathogenesis of ataxia telangiectasia. Annu Rev Pathol. 2012;7:303\u2013321. doi: 10.1146/annurev-pathol-011811-132509.", "ArticleIdList": ["10.1146/annurev-pathol-011811-132509", "22035194"]}, {"Citation": "Sahama I, Sinclair K, Pannek K, Lavin M, Rose S. Radiological imaging in ataxia telangiectasia: a review. Cerebellum. 2014;13(4):521\u2013530. doi: 10.1007/s12311-014-0557-4.", "ArticleIdList": ["10.1007/s12311-014-0557-4", "24683014"]}, {"Citation": "Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11:159. doi: 10.1186/s13023-016-0543-7.", "ArticleIdList": ["10.1186/s13023-016-0543-7", "PMC5123280", "27884168"]}, {"Citation": "Anheim M, Monga B, Fleury M, Charles P, Barbot C, Salih M, Delaunoy JP, Fritsch M, Arning L, Synofzik M, Sch\u00f6ls L, Sequeiros J, Goizet C, Marelli C, Le Ber I, Koht J, Gazulla J, De Bleecker J, Mukhtar M, Drouot N, Ali-Pacha L, Benhassine T, Chbicheb M, M\u2019Zahem A, Hamri A, Chabrol B, Pouget J, Murphy R, Watanabe M, Coutinho P, Tazir M, Durr A, Brice A, Tranchant C, Koenig M. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain. 2009;132(10):2688\u20132698. doi: 10.1093/brain/awp211.", "ArticleIdList": ["10.1093/brain/awp211", "19696032"]}, {"Citation": "Coutinho P, Barbot C. Ataxia with oculomotor apraxia type 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. GeneReviews\u00ae [Internet] Seattle: University of Washington; 2015."}, {"Citation": "Moreira M-C, Koenig M. Ataxia with oculomotor apraxia type 2. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. GeneReviews\u00ae [Internet] Seattle: University of Washington; 2018.", "ArticleIdList": ["20301333"]}, {"Citation": "Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med. 2009;57(8):830\u2013836. doi: 10.2310/JIM.0b013e3181af59c4.", "ArticleIdList": ["10.2310/JIM.0b013e3181af59c4", "PMC2787702", "19574929"]}, {"Citation": "Currie S, Hadjivassiliou M, Craven IJ, Wilkinson ID, Griffiths PD, Hoggard N. Magnetic resonance imaging biomarkers in patients with progressive ataxia: current status and future direction. Cerebellum. 2013;12(2):245\u2013266. doi: 10.1007/s12311-012-0405-3.", "ArticleIdList": ["10.1007/s12311-012-0405-3", "22828959"]}, {"Citation": "Tassone F, Hall DA. FXTAS, FXPOI, and other premutation disorders. 2. Cham: Springer; 2016."}, {"Citation": "Braga-Neto P, Pedroso JL, Kuo S-H, Marcondes Junior CF, Teive HAG, Barsottini OGP. Current concepts in the treatment of hereditary ataxias. Arq Neuropsiquiatr. 2016;74(3):244\u2013252. doi: 10.1590/0004-282X20160038.", "ArticleIdList": ["10.1590/0004-282X20160038", "PMC6089349", "27050855"]}, {"Citation": "Sullivan R, Yau WY, O\u2019Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol. 2019;266(2):533\u2013544. doi: 10.1007/s00415-018-9076-4.", "ArticleIdList": ["10.1007/s00415-018-9076-4", "PMC6373366", "30284037"]}, {"Citation": "Schniepp R, Strupp M, Wuehr M, Jahn K, Dieterich M, Brandt T, Feil K. Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia\u2014a case series. Cerebellum Ataxias. 2016;3:8. doi: 10.1186/s40673-016-0046-2.", "ArticleIdList": ["10.1186/s40673-016-0046-2", "PMC4828858", "27073690"]}, {"Citation": "National Library of Medicine (U.S.). N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T). https://clinicaltrials.gov/ct2/show/NCT03759678 (2018). NLM identifier: NCT03759678. Accessed 25 July 2020"}, {"Citation": "Butler MS, Fontaine F, Cooper MA. Natural product libraries: assembly, maintenance, and screening. Planta Med. 2014;80(14):1161\u20131170. doi: 10.1055/s-0033-1360109.", "ArticleIdList": ["10.1055/s-0033-1360109", "24310213"]}, {"Citation": "Pohl F, Kong Thoo Lin P. The potential use of plant natural products and plant extracts with antioxidant properties for the prevention/treatment of neurodegenerative diseases: in vitro, in vivo and clinical trials. Molecules. 2018;23(12):3283. doi: 10.3390/molecules23123283.", "ArticleIdList": ["10.3390/molecules23123283", "PMC6321248", "30544977"]}, {"Citation": "Ayaz M, Ullah F, Sadiq A, Kim MO, Ali T. Natural products-based drugs: potential therapeutics against Alzheimer\u2019s disease and other neurological disorders. Front Pharmacol. 2019;10:1417. doi: 10.3389/fphar.2019.01417.", "ArticleIdList": ["10.3389/fphar.2019.01417", "PMC6889855", "31849668"]}, {"Citation": "Clardy J, Walsh C. Lessons from natural molecules. Nature. 2004;432(7019):829\u2013837. doi: 10.1038/nature03194.", "ArticleIdList": ["10.1038/nature03194", "15602548"]}, {"Citation": "Guo Z. The modification of natural products for medical use. Acta Pharm Sin B. 2017;7(2):119\u2013136. doi: 10.1016/j.apsb.2016.06.003.", "ArticleIdList": ["10.1016/j.apsb.2016.06.003", "PMC5343118", "28303218"]}, {"Citation": "Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015;14(2):111\u2013129. doi: 10.1038/nrd4510.", "ArticleIdList": ["10.1038/nrd4510", "25614221"]}, {"Citation": "Zhang R, Zhu X, Bai H, Ning K. Network pharmacology databases for traditional Chinese medicine: review and assessment. Front Pharmacol. 2019;10:123. doi: 10.3389/fphar.2019.00123.", "ArticleIdList": ["10.3389/fphar.2019.00123", "PMC6393382", "30846939"]}, {"Citation": "Chen X, Decker M. Multi-target compounds acting in the central nervous system designed from natural products. Curr Med Chem. 2013;20(13):1673\u20131685. doi: 10.2174/0929867311320130007.", "ArticleIdList": ["10.2174/0929867311320130007", "23410166"]}, {"Citation": "Koeberle A, Werz O. Multi-target approach for natural products in inflammation. Drug Discov Today. 2014;19(12):1871\u20131882. doi: 10.1016/j.drudis.2014.08.006.", "ArticleIdList": ["10.1016/j.drudis.2014.08.006", "25172801"]}, {"Citation": "Salvador-Reyes LA, Luesch H. Biological targets and mechanisms of action of natural products from marine cyanobacteria. Nat Prod Rep. 2015;32(3):478\u2013503. doi: 10.1039/c4np00104d.", "ArticleIdList": ["10.1039/c4np00104d", "PMC4344435", "25571978"]}, {"Citation": "Lozano F. Basic theories of traditional Chinese medicine. In: Lin Y-C, Hsu ES-Z, editors. Acupuncture for Pain Management. New York: Springer; 2014."}, {"Citation": "Marshall AC. Traditional Chinese medicine and clinical pharmacology. In: Hock F, Gralinski M, editors. Drug discovery and evaluation: methods in clinical pharmacology. Cham: Springer; 2020. pp. 455\u201382."}, {"Citation": "Wu T-Y, Chen C-P, Jinn T-R. Traditional Chinese medicines and Alzheimer\u2019s disease. Taiwan J Obstet Gynecol. 2011;50(2):131\u2013135. doi: 10.1016/j.tjog.2011.04.004.", "ArticleIdList": ["10.1016/j.tjog.2011.04.004", "21791295"]}, {"Citation": "Chen I-C, Chang C-N, Chen W-L, Lin T-H, Chao C-Y, Lin C-H, Lin H-Y, Cheng M-L, Chiang M-C, Lin J-Y, Wu Y-R, Lee-Chen G-J, Chen C-M. Targeting ubiquitin proteasome pathway with traditional Chinese medicine for treatment of spinocerebellar ataxia type 3. Am J Chin Med. 2019;47(1):63\u201395. doi: 10.1142/s0192415x19500046.", "ArticleIdList": ["10.1142/s0192415x19500046", "30612452"]}, {"Citation": "Chen I-C, Chang K-H, Chen Y-J, Chen Y-C, Lee-Chen G-J, Chen C-M. Pueraria lobata and daidzein reduce cytotoxicity by enhancing ubiquitin-proteasome system function in SCA3-iPSC-derived neurons. Oxid Med Cell Longev. 2019;2019:8130481. doi: 10.1155/2019/8130481.", "ArticleIdList": ["10.1155/2019/8130481", "PMC6800904", "31687087"]}, {"Citation": "Chou A-H, Chen Y-L, Chiu C-C, Yuan S-J, Weng Y-H, Yeh T-H, Lin Y-L, Fang J-M, Wang H-L. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and symptoms of ataxia in the SCA3 transgenic mouse. Neuropharmacology. 2015;99:308\u2013317. doi: 10.1016/j.neuropharm.2015.08.009.", "ArticleIdList": ["10.1016/j.neuropharm.2015.08.009", "26254860"]}, {"Citation": "Chang K-H, Chen W-L, Wu Y-R, Lin T-H, Wu Y-C, Chao C-Y, Lin J-Y, Lee L-C, Chen Y-C, Lee-Chen G-J, Chen C-M. Aqueous extract of Gardenia jasminoides targeting oxidative stress to reduce polyQ aggregation in cell models of spinocerebellar ataxia 3. Neuropharmacology. 2014;81:166\u2013175. doi: 10.1016/j.neuropharm.2014.01.032.", "ArticleIdList": ["10.1016/j.neuropharm.2014.01.032", "24486383"]}, {"Citation": "Chen C-M, Weng Y-T, Chen W-L, Lin T-H, Chao C-Y, Lin C-H, Chen I-C, Lee L-C, Lin H-Y, Wu Y-R, Chen Y-C, Chang K-H, Tang H-Y, Cheng M-L, Lee-Chen G-J, Lin J-Y. Aqueous extract of Glycyrrhiza inflata inhibits aggregation by upregulating PPARGC1A and NFE2L2\u2013ARE pathways in cell models of spinocerebellar ataxia 3. Free Radic Biol Med. 2014;71:339\u2013350. doi: 10.1016/j.freeradbiomed.2014.03.023.", "ArticleIdList": ["10.1016/j.freeradbiomed.2014.03.023", "24675225"]}, {"Citation": "Chang K-H, Chen W-L, Lee L-C, Lin C-H, Kung P-J, Lin T-H, Wu Y-C, Wu Y-R, Chen Y-C, Lee G-J, Chen C-M. Aqueous extract of Paeonia lactiflora and paeoniflorin as aggregation reducers targeting chaperones in cell models of spinocerebellar ataxia 3. Evid Based Complement Alternat Med. 2013;2013:471659. doi: 10.1155/2013/471659.", "ArticleIdList": ["10.1155/2013/471659", "PMC3596917", "23533486"]}, {"Citation": "Pohl F, Teixeira-Castro A, Costa MD, Lindsay V, Fi\u00faza-Fernandes J, Goua M, Bermano G, Russell W, Maciel P, Kong Thoo Lin P. Kong Thoo Lin P. GST-4-dependent suppression of neurodegeneration in C. elegans models of Parkinson\u2019s and Machado-Joseph disease by rapeseed pomace extract supplementation. Front Neurosci. 2019;13:1091. doi: 10.3389/fnins.2019.01091.", "ArticleIdList": ["10.3389/fnins.2019.01091", "PMC6811615", "31680826"]}, {"Citation": "Huang D-S, Lin H-Y, Lee-Chen G-J, Hsieh-Li H-M, Wu C-H, Lin J-Y. Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17. Drug Des Devel Ther. 2016;10:723\u2013731. doi: 10.2147/DDDT.S98156.", "ArticleIdList": ["10.2147/DDDT.S98156", "PMC4762588", "26937174"]}, {"Citation": "Okabe T, Fujisawa M, Sekiya T, Ichikawa Y, Goto J. Successful treatment of spinocerebellar ataxia 6 with medicinal herbs. Geriatr Gerontol Int. 2007;7(2):195\u2013197. doi: 10.1111/j.1447-0594.2007.00378.x.", "ArticleIdList": ["10.1111/j.1447-0594.2007.00378.x"]}, {"Citation": "Okabe T. Remission induction of spinocerebellar ataxia 6 with medicinal herbs. J Aging Neuro Psychol. 2018 doi: 10.29011/janp-108.100008.", "ArticleIdList": ["10.29011/janp-108.100008"]}, {"Citation": "Chen C-M, Chen W-L, Hung C-T, Lin T-H, Lee M-C, Chen I-C, Lin C-H, Chao C-Y, Wu Y-R, Chang K-H, Hsieh-Li H-M, Lee-Chen G-J. Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models. Aging. 2019;11(3):986\u20131007. doi: 10.18632/aging.101804.", "ArticleIdList": ["10.18632/aging.101804", "PMC6382417", "30760647"]}, {"Citation": "Lew S-Y, Yow Y-Y, Lim L-W, Wong K-H. Antioxidant-mediated protective role of Hericium erinaceus (Bull.: Fr.) Pers. against oxidative damage in fibroblasts from Friedreich\u2019s ataxia patient. Food Sci Technol. 2020;40(Suppl 1):264\u2013272. doi: 10.1590/fst.09919.", "ArticleIdList": ["10.1590/fst.09919"]}, {"Citation": "McIntosh CS, Aung-Htut MT, Fletcher S, Wilton SD. Polyglutamine ataxias: from clinical and molecular features to current therapeutic strategies. J Genet Syndr Gene Ther. 2017;8(2):1\u201317. doi: 10.4172/2157-7412.1000319.", "ArticleIdList": ["10.4172/2157-7412.1000319"]}, {"Citation": "Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 2008;31(10):521\u2013528. doi: 10.1016/j.tins.2008.07.004.", "ArticleIdList": ["10.1016/j.tins.2008.07.004", "PMC2580745", "18778858"]}, {"Citation": "Dantuma NP, Bott LC. The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front Mol Neurosci. 2014;7:70. doi: 10.3389/fnmol.2014.00070.", "ArticleIdList": ["10.3389/fnmol.2014.00070", "PMC4117186", "25132814"]}, {"Citation": "Bader M, Steller H. Regulation of cell death by the ubiquitin\u2013proteasome system. Curr Opin Cell Biol. 2009;21(6):878\u2013884. doi: 10.1016/j.ceb.2009.09.005.", "ArticleIdList": ["10.1016/j.ceb.2009.09.005", "PMC2818673", "19850458"]}, {"Citation": "Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y-H, Ciechanover A, Orr HT, Beaudet AL, Zoghbi HY. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron. 1999;24(4):879\u2013892. doi: 10.1016/S0896-6273(00)81035-1.", "ArticleIdList": ["10.1016/S0896-6273(00)81035-1", "10624951"]}, {"Citation": "Matilla A, Gorbea C, Einum DD, Townsend J, Michalik A, van Broeckhoven C, Jensen CC, Murphy KJ, Pt\u00e1cek LJ, Fu Y-H. Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex. Hum Mol Genet. 2001;10(24):2821\u20132831. doi: 10.1093/hmg/10.24.2821.", "ArticleIdList": ["10.1093/hmg/10.24.2821", "11734547"]}, {"Citation": "Chai Y, Berke SS, Cohen RE, Paulson HL. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem. 2004;279(5):3605\u20133611. doi: 10.1074/jbc.M310939200.", "ArticleIdList": ["10.1074/jbc.M310939200", "14602712"]}, {"Citation": "Due\u00f1as AM, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain. 2006;129(6):1357\u20131370. doi: 10.1093/brain/awl081.", "ArticleIdList": ["10.1093/brain/awl081", "16613893"]}, {"Citation": "Myeku N, Wang H, Figueiredo-Pereira ME. cAMP stimulates the ubiquitin/proteasome pathway in rat spinal cord neurons. Neurosci Lett. 2012;527(2):126\u2013131. doi: 10.1016/j.neulet.2012.08.051.", "ArticleIdList": ["10.1016/j.neulet.2012.08.051", "PMC3464398", "22982149"]}, {"Citation": "Defer N, Best-Belpomme M, Hanoune J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol. 2000;279(3):F400\u2013F416. doi: 10.1152/ajprenal.2000.279.3.F400.", "ArticleIdList": ["10.1152/ajprenal.2000.279.3.F400", "10966920"]}, {"Citation": "Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev. 2017;2017:8416763. doi: 10.1155/2017/8416763.", "ArticleIdList": ["10.1155/2017/8416763", "PMC5551541", "28819546"]}, {"Citation": "Kim S-J, Kim TS, Hong S, Rhim H, Kim IY, Kang S. Oxidative stimuli affect polyglutamine aggregation and cell death in human mutant ataxin-1-expressing cells. Neurosci Lett. 2003;348(1):21\u201324. doi: 10.1016/S0304-3940(03)00657-8.", "ArticleIdList": ["10.1016/S0304-3940(03)00657-8", "12893416"]}, {"Citation": "Xiao L, Li H, Zhang J, Yang F, Huang A, Deng J, Liang M, Ma F, Hu M, Huang Z. Salidroside protects Caenorhabditis elegans neurons from polyglutamine-mediated toxicity by reducing oxidative stress. Molecules. 2014;19(6):7757\u20137769. doi: 10.3390/molecules19067757.", "ArticleIdList": ["10.3390/molecules19067757", "PMC6270757", "24918543"]}, {"Citation": "Pacheco LS, da Silveira AF, Trott A, Houenou LJ, Algarve TD, Bell\u00f3 C, Lenz AF, M\u00e2nica-Cattani MF, da Cruz IBM. Association between Machado-Joseph disease and oxidative stress biomarkers. Mutat Res. 2013;757(2):99\u2013103. doi: 10.1016/j.mrgentox.2013.06.023.", "ArticleIdList": ["10.1016/j.mrgentox.2013.06.023", "23994570"]}, {"Citation": "Giuliano P, de Cristofaro T, Affaitati A, Pizzulo GM, Feliciello A, Criscuolo C, De Michele G, Filla A, Avvedimento EV, Varrone S. DNA damage induced by polyglutamine-expanded proteins. Hum Mol Genet. 2003;12(18):2301\u20132309. doi: 10.1093/hmg/ddg242.", "ArticleIdList": ["10.1093/hmg/ddg242", "12915485"]}, {"Citation": "Bertoni A, Giuliano P, Galgani M, Rotoli D, Ulianich L, Adornetto A, Santillo MR, Porcellini A, Avvedimento VE. Early and late events induced by polyQ-expanded proteins: identification of a common pathogenic property of polyQ-expanded proteins. J Biol Chem. 2011;286(6):4727\u20134741. doi: 10.1074/jbc.M110.156521.", "ArticleIdList": ["10.1074/jbc.M110.156521", "PMC3039353", "21115499"]}, {"Citation": "Aquilano K, Baldelli S, Pagliei B, Cannata SM, Rotilio G, Ciriolo MR. p53 orchestrates the PGC-1\u03b1-mediated antioxidant response upon mild redox and metabolic imbalance. Antioxid Redox Signal. 2013;18(4):386\u2013399. doi: 10.1089/ars.2012.4615.", "ArticleIdList": ["10.1089/ars.2012.4615", "PMC3526895", "22861165"]}, {"Citation": "Jauslin ML, Vertuani S, Durini E, Buzzoni L, Ciliberti N, Verdecchia S, Palozza P, Meier T, Manfredini S. Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich ataxia. Mol Cell Biochem. 2007;302(1\u20132):79\u201385. doi: 10.1007/s11010-007-9429-2.", "ArticleIdList": ["10.1007/s11010-007-9429-2", "17476463"]}, {"Citation": "Piemonte F, Pastore A, Tozzi G, Tagliacozzi D, Santorelli FM, Carrozzo R, Casali C, Damiano M, Federici G, Bertini E. Glutathione in blood of patients with Friedreich\u2019s ataxia. Eur J Clin Invest. 2001;31(11):1007\u20131011. doi: 10.1046/j.1365-2362.2001.00922.x.", "ArticleIdList": ["10.1046/j.1365-2362.2001.00922.x", "11737244"]}, {"Citation": "Auch\u00e8re F, Santos R, Planamente S, Lesuisse E, Camadro J-M. Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich\u2019s ataxia. Hum Mol Genet. 2008;17(18):2790\u20132802. doi: 10.1093/hmg/ddn178.", "ArticleIdList": ["10.1093/hmg/ddn178", "18562474"]}, {"Citation": "Clark E, Johnson J, Dong YN, Mercado-Ayon E, Warren N, Zhai M, McMillan E, Salovin A, Lin H, Lynch DR. Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease. Neuronal. Signal. 2018;2(4):NS20180060.", "ArticleIdList": ["PMC7373238", "32714592"]}, {"Citation": "Gomes CM, Santos R. Neurodegeneration in Friedreich\u2019s ataxia: from defective frataxin to oxidative stress. Oxid Med Cell Longev. 2013;2013:487534. doi: 10.1155/2013/487534.", "ArticleIdList": ["10.1155/2013/487534", "PMC3725840", "23936609"]}, {"Citation": "Anderson PR, Kirby K, Orr WC, Hilliker AJ, Phillips JP. Hydrogen peroxide scavenging rescues frataxin deficiency in a Drosophila model of Friedreich\u2019s ataxia. Proc Natl Acad Sci U S A. 2008;105(2):611\u2013616. doi: 10.1073/pnas.0709691105.", "ArticleIdList": ["10.1073/pnas.0709691105", "PMC2206584", "18184803"]}, {"Citation": "Santos R, Lefevre S, Sliwa D, Seguin A, Camadro J-M, Lesuisse E. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal. 2010;13(5):651\u2013690. doi: 10.1089/ars.2009.3015.", "ArticleIdList": ["10.1089/ars.2009.3015", "PMC2924788", "20156111"]}, {"Citation": "Lefevre S, Brossas C, Auch\u00e8re F, Boggetto N, Camadro J-M, Santos R. Apn1 AP-endonuclease is essential for the repair of oxidatively damaged DNA bases in yeast frataxin-deficient cells. Hum Mol Genet. 2012;21(18):4060\u20134072. doi: 10.1093/hmg/dds230.", "ArticleIdList": ["10.1093/hmg/dds230", "PMC3428155", "22706278"]}, {"Citation": "Carletti B, Piemonte F. Friedreich\u2019s ataxia: a neuronal point of view on the oxidative stress hypothesis. Antioxidants. 2014;3(3):592\u2013603. doi: 10.3390/antiox3030592.", "ArticleIdList": ["10.3390/antiox3030592", "PMC4665420", "26785073"]}, {"Citation": "Takahashi K, Tatsunami R, Oba T, Tampo Y. Buthionine sulfoximine promotes methylglyoxal-induced apoptotic cell death and oxidative stress in endothelial cells. Biol Pharm Bull. 2010;33(4):556\u2013560. doi: 10.1248/bpb.33.556.", "ArticleIdList": ["10.1248/bpb.33.556", "20410585"]}, {"Citation": "Arruda AP, Hotamisligil GS. Calcium homeostasis and organelle function in the pathogenesis of obesity and diabetes. Cell Metab. 2015;22(3):381\u2013397. doi: 10.1016/j.cmet.2015.06.010.", "ArticleIdList": ["10.1016/j.cmet.2015.06.010", "PMC4558313", "26190652"]}, {"Citation": "Tang T-S, Tu H, Chan EYW, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1. Neuron. 2003;39(2):227\u2013239. doi: 10.1016/S0896-6273(03)00366-0.", "ArticleIdList": ["10.1016/S0896-6273(03)00366-0", "PMC3220623", "12873381"]}, {"Citation": "Tang T-S, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llin\u00e1s R, Kristal BS, Hayden MR, Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington\u2019s disease. Proc Natl Acad Sci U S A. 2005;102(7):2602\u20132607. doi: 10.1073/pnas.0409402102.", "ArticleIdList": ["10.1073/pnas.0409402102", "PMC548984", "15695335"]}, {"Citation": "Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, Doerr J, Ladewig J, Mertens J, T\u00fcting T, Hoffmann P, Klockgether T, Evert BO, W\u00fcllner U, Br\u00fcstle O. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011;480(7378):543\u2013546. doi: 10.1038/nature10671.", "ArticleIdList": ["10.1038/nature10671", "22113611"]}, {"Citation": "Egorova P, Popugaeva E, Bezprozvanny I. Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer\u2019s disease. Semin Cell Dev Biol. 2015;40:127\u2013133. doi: 10.1016/j.semcdb.2015.03.010.", "ArticleIdList": ["10.1016/j.semcdb.2015.03.010", "PMC4433580", "25846864"]}, {"Citation": "Barski JJ, Hartmann J, Rose CR, Hoebeek F, M\u00f6rl K, Noll-Hussong M, De Zeeuw CI, Konnerth A, Meyer M. Calbindin in cerebellar Purkinje cells is a critical determinant of the precision of motor coordination. J Neurosci. 2003;23(8):3469\u20133477. doi: 10.1523/JNEUROSCI.23-08-03469.2003.", "ArticleIdList": ["10.1523/JNEUROSCI.23-08-03469.2003", "PMC6742296", "12716955"]}, {"Citation": "Schmidt H. Three functional facets of calbindin D-28k. Front Mol Neurosci. 2012;5:25. doi: 10.3389/fnmol.2012.00025.", "ArticleIdList": ["10.3389/fnmol.2012.00025", "PMC3304297", "22435048"]}, {"Citation": "Park C-J, Seo Y-S. Heat shock proteins: a review of the molecular chaperones for plant immunity. Plant Pathol J. 2015;31(4):323\u2013333. doi: 10.5423/PPJ.RW.08.2015.0150.", "ArticleIdList": ["10.5423/PPJ.RW.08.2015.0150", "PMC4677741", "26676169"]}, {"Citation": "Miller DJ, Fort PE. Heat shock proteins regulatory role in neurodevelopment. Front Neurosci. 2018;12:821. doi: 10.3389/fnins.2018.00821.", "ArticleIdList": ["10.3389/fnins.2018.00821", "PMC6244093", "30483047"]}, {"Citation": "Chen C-M, Lee L-C, Soong B-W, Fung H-C, Hsu W-C, Lin P-Y, Huang H-J, Chen F-L, Lin C-Y, Lee-Chen G-J, Wu Y-R. SCA17 repeat expansion: mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications. Clin Chim Acta. 2010;411(5\u20136):375\u2013380. doi: 10.1016/j.cca.2009.12.002.", "ArticleIdList": ["10.1016/j.cca.2009.12.002", "20004653"]}, {"Citation": "Lee L-C, Chen C-M, Wang H-C, Hsieh H-H, Chiu I-S, Su M-T, Hsieh-Li H-M, Wu C-H, Lee G-C, Lee-Chen G-J, Lin J-Y. Role of the CCAAT-binding protein NFY in SCA17 pathogenesis. PLoS ONE. 2012;7(4):e35302. doi: 10.1371/journal.pone.0035302.", "ArticleIdList": ["10.1371/journal.pone.0035302", "PMC3328435", "22530004"]}, {"Citation": "Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, Dillmann WH, Zoghbi HY. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet. 2001;10(14):1511\u20131518. doi: 10.1093/hmg/10.14.1511.", "ArticleIdList": ["10.1093/hmg/10.14.1511", "11448943"]}, {"Citation": "Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo A-P, Rubinsztein DC. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet. 2002;11(9):1137\u20131151. doi: 10.1093/hmg/11.9.1137.", "ArticleIdList": ["10.1093/hmg/11.9.1137", "11978772"]}, {"Citation": "Fujimoto M, Takaki E, Hayashi T, Kitaura Y, Tanaka Y, Inouye S, Nakai A. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem. 2005;280(41):34908\u201334916. doi: 10.1074/jbc.M506288200.", "ArticleIdList": ["10.1074/jbc.M506288200", "16051598"]}, {"Citation": "Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem. 2008;283(38):26188\u201326197. doi: 10.1074/jbc.M710521200.", "ArticleIdList": ["10.1074/jbc.M710521200", "PMC3258858", "18632670"]}, {"Citation": "Kuo Y, Ren S, Lao U, Edgar BA, Wang T. Suppression of polyglutamine protein toxicity by co-expression of a heat-shock protein 40 and a heat-shock protein 110. Cell Death Dis. 2013;4(10):e833. doi: 10.1038/cddis.2013.351.", "ArticleIdList": ["10.1038/cddis.2013.351", "PMC3824661", "24091676"]}, {"Citation": "Beutler JA. Natural products as a foundation for drug discovery. Curr Protoc Pharmacol. 2019;86(1):e67.", "ArticleIdList": ["PMC7442317", "31539923"]}, {"Citation": "Krause J, Tobin G. Discovery, development, and regulation of natural products. In: Kulka M, editor. Using old solutions to new problems-natural drug discovery in the 21st century. London: IntechOpen; 2013. pp. 1\u201335."}, {"Citation": "Atanasov AG, Waltenberger B, Pferschy-Wenzig E-M, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, Rollinger JM. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582\u20131614. doi: 10.1016/j.biotechadv.2015.08.001.", "ArticleIdList": ["10.1016/j.biotechadv.2015.08.001", "PMC4748402", "26281720"]}, {"Citation": "Canter PH, Thomas H, Ernst E. Bringing medicinal plants into cultivation: opportunities and challenges for biotechnology. Trends Biotechnol. 2005;23(4):180\u2013185. doi: 10.1016/j.tibtech.2005.02.002.", "ArticleIdList": ["10.1016/j.tibtech.2005.02.002", "15780709"]}, {"Citation": "Perdomini M, Hick A, Puccio H, Pook MA. Animal and cellular models of Friedreich ataxia. J Neurochem. 2013;126(Suppl 1):65\u201379. doi: 10.1111/jnc.12219.", "ArticleIdList": ["10.1111/jnc.12219", "23859342"]}, {"Citation": "Matos CA, de Almeida LP, N\u00f3brega C. Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy. J Neurochem. 2019;148(1):8\u201328. doi: 10.1111/jnc.14541.", "ArticleIdList": ["10.1111/jnc.14541", "29959858"]}, {"Citation": "Cendelin J. From mice to men: lessons from mutant ataxic mice. Cerebellum Ataxias. 2014;1:4. doi: 10.1186/2053-8871-1-4.", "ArticleIdList": ["10.1186/2053-8871-1-4", "PMC4549131", "26331028"]}, {"Citation": "Faber J, Fonseca LM. How sample size influences research outcomes. Dental Press J Orthod. 2014;19(4):27\u201329. doi: 10.1590/2176-9451.19.4.027-029.ebo.", "ArticleIdList": ["10.1590/2176-9451.19.4.027-029.ebo", "PMC4296634", "25279518"]}, {"Citation": "Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239\u20131249. doi: 10.1111/j.1476-5381.2010.01127.x.", "ArticleIdList": ["10.1111/j.1476-5381.2010.01127.x", "PMC3058157", "21091654"]}, {"Citation": "Keum J, Yoo S, Lee D, Nam H. Prediction of compound-target interactions of natural products using large-scale drug and protein information. BMC Bioinformatics. 2016;17(Suppl 6):219. doi: 10.1186/s12859-016-1081-y.", "ArticleIdList": ["10.1186/s12859-016-1081-y", "PMC4965709", "27490208"]}, {"Citation": "Law BYK, Wu AG, Wang MJ, Zhu YZ. Chinese medicine: a hope for neurodegenerative diseases? J Alzheimers Dis. 2017;60(s1):S151\u2013S160. doi: 10.3233/JAD-170374.", "ArticleIdList": ["10.3233/JAD-170374", "28671133"]}, {"Citation": "Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018;19(5):299\u2013310. doi: 10.1038/nrg.2018.4.", "ArticleIdList": ["10.1038/nrg.2018.4", "PMC5990367", "29479082"]}, {"Citation": "Woollard PM, Mehta NAL, Vamathevan JJ, Van Horn S, Bonde BK, Dow DJ. The application of next-generation sequencing technologies to drug discovery and development. Drug Discov Today. 2011;16(11\u201312):512\u2013519. doi: 10.1016/j.drudis.2011.03.006.", "ArticleIdList": ["10.1016/j.drudis.2011.03.006", "21440664"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "8", "Day": "27"}, {"Year": "2020", "Month": "12", "Day": "11"}, {"Year": "2020", "Month": "11", "Day": "17"}, {"Year": "2021", "Month": "1", "Day": "29", "Hour": "5", "Minute": "38"}, {"Year": "2021", "Month": "1", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "1", "Day": "30", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "1", "Day": "28"}], "PublicationStatus": "epublish", "ArticleIdList": ["33509239", "PMC7841890", "10.1186/s13020-020-00414-x", "10.1186/s13020-020-00414-x"]}}], "PubmedBookArticle": []}